Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 20/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17056292 | 0.87 | S1PR1 (0.66) | S1PR1 | |
| SCHEMBL17056473 | 0.87 | S1PR1 (1.00) | S1PR1 | |
| SCHEMBL17056318 | 0.85 | S1PR1 (0.78) | S1PR1 | |
| SCHEMBL17056319 | 0.84 | S1PR1 (0.77) | S1PR1 | |
| SCHEMBL17056323 | 0.84 | S1PR1 (1.00) | S1PR1 | |
| SCHEMBL17056320 | 0.84 | S1PR1 (1.00) | S1PR1 | |
| SCHEMBL17056302 | 0.83 | S1PR1 (0.75) | S1PR1 | |
| SCHEMBL17056304 | 0.83 | S1PR1 (0.74) | S1PR1 | |
| SCHEMBL17056305 | 0.83 | S1PR1 (0.74) | S1PR1 | |
| SCHEMBL17056309 | 0.81 | S1PR1 (0.88) | S1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9988350-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-05 | — | — | US | disclosed |
| US-9988350-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2018-06-05 | — | — | US | disclosed |
| US-20170320821-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-20170320821-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-11-09 | — | — | US | disclosed |
| US-9718771-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-9718771-B2 | Aniline derivative, pharmaceutical composition containing same, and use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2017-08-01 | — | — | US | disclosed |
| US-20160362368-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2016-12-15 | — | — | US | disclosed |
| US-20160362368-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2016-12-15 | — | — | US | disclosed |
| WO-2015129859-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | キッセイ薬品工業株式会社 | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362368-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | S1PR1, S1PR3, S1PR2 | S1PR1 1/4885 |
| US-20170320821-A1 | NOVEL ANILINE DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | S1PR3, S1PR1, S1PR2 | S1PR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.